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IEA Current Policies Scenario











2005 2010 2015 2020 2025 2030
Supplementing conventional fossil energies 
with new and clean energies has become a necessity
50
100




 Global demand for energy grows by 27% from 2010 to 2030 (1.2%/y. CAGR)
 Fossil energies still represent 75% of energy supply in 2030 but oil demand 
will be constrained by supply earlier




 Renewable energy is the second largest contributor to CO2 emissions 
abatement
 Compound Annual Growth Rate 2009-2030 New Policies scenario :
Solar: +22%/y Biomass: +6.5%/y Nuclear: +2.2%/y
Wind: +10%/y Hydro: +2%/y
Source : IEA World Energy Outlook 2010
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Solar power: early stages of market consolidation, accelerating 
demand driving strong cost reduction
Biotechnology for fuels and chemicals: even earlier stage, value 
chain under construction
In both cases, technology is key to competitiveness and potentially 
disruptive
Building strong positions in two young markets
Become a leader in solar power
Best current technology and ongoing R&D 
to reduce costs and prepare next 
generations
Integrate along the photovoltaics value 
chain
Leverage Total’s access to markets
Produce drop-in biomolecules
on an industrial scale
Differentiate through technology 
development
Start production from sugar crops while 
preparing next generation 
transformation process
Reach industrial scale for advanced 
biofuels by ~2015
Total’s strategy in renewables
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Network of collaborations with academic labs and startups
 Building win-win partnerships is core to the model: complementarity and alignment
 We strive to develop expertise, know-how and intellectual property
 Strategic partnerships with startups : equity investment, R&D and industrial collaboration
Corporate venture fund invests in partners at periphery of strategic focus
European
Network
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Production of input 
























Motivations for biofuels and biobased chemicals
From the perspective of an integrated energy/chemicals company
Will biofuels grow to become an important part of the fuel mix ?
 Short to mid-term: very probably.
 Biofuels incorporation mandates in the EU and US create long-term demand
 …increasingly unbalanced between diesel and gasoline in Europe
 …..while tensions are anticipated on vegetable oils
 Emerging initiatives to promote biojet
 Need for hydrocarbon production technology 













Will the use of renewable resources and « green » processes in 
the chemical industry grow ?
 One needs biobased molecules to renewably produce…molecules
 Technology push: space of substitutable products and intermediates is growing
 Stakeholders are pulling toward renewable feedstocks but with little premium for 
the time being  green
 Need to develop bioproduction technology applicable to a variety 











Réel 2009 Estimations 2020
Objectifs 2020 selon 
réglementations & plans 













50 % de l'objectif 




















Cereals, oilseeds, sugar crops,…
Limited quantities (variable
from place to place) 
high costs: >  4 to 6 €/GJ
Competition for use:
Food, Industry
Bio Energy Potential: 100-300 EJ
Dedicated crops:
Higher potential if land is available
Costs: 3 to 6 €/GJ 
Competition for use: agricultural land
Bio Energy Potential: 60-150 EJ
Agri and Forestry 
wastes:
Significant volumes but often 
need collection, storage and 
conditioning organization
Industrial and home wastes 
(wet biomass):
Significant volumes
Low delivery costs in the vicinity : < 2 €/GJ
> 2025> 2015
Costs: 2 to 5 €/GJ
Competition for use:
litter, fertilizer, wood industry
Bio Energy Potential: 45-220 EJ
Transformation technology at R&D stage
Bio Energy Potential: 10-100 EJ
2005
Time
…but local potential, constraints, choices, and practices matter more.
Sugarcane in Brazil is currently the only biomass feedstock combining viable 
economics, environmental acceptability, and large potential for 
growth…until cheap sugars from lignocellulosis materialize
Emerg ingbioproduction routes need to meet emerging
environmental acceptability criteria
 Feedstock largely drives GHG emissions performance for a given feedstock -
transformation route-target molecule route.  
 Land and water are scarce resources, for which arbitrage is necessary
 Sugarcane in Brazil has an acceptable environmental footprint
 GHG emissions and biofuels mandates set the stage for the biofuels industry
development ; no equivalent indicators / drivers for biobased chemicals or jet…yet?
Total R&D in Cleantech -- Lux Executive Summit, Boston, April 2012











































Matière première CAPEX 
OPEX Valorisation des co-produits 
Distribution Coût de revient global
1G 1.5G 2G
Biosourced molecules need to reach production costs competitive
with hydrocarbon alternatives & market-compatible volumes 
Emerging industry players developing advanced transformation technologies 
need to 
 Scale-up production routes to commercial-scale operations
 Secure access to feedstocks
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Biomass transformation routes : a global view
11

















TOTAL property - CONFIDENTIAL
Stakes
 From a diversity of feedstocks to a 
multitude of products and markets
 From dedicated routes to a “lego” of 
technologies through thermal, catalytic and 
biotechnological conversions
Biotechnology for fuels and chemicals: our priorities
 Plants-to-Sugars-to-Molecules: synthetic biology accelerates
development, creates new routes and introduces flexibility








Algae & phototrophic 
microbes















Metabolic Engineering and Synthetic Biology
Biotechnology:
 Yeast/Bacterial cells: chemical factories
 Enzymatic catalysis
 Specific Products
The biochemical capabilities of 
yeast/bacteria is encoded in its genome:
 Each gene  = enzyme = catalysis of a specific 
reaction
 ~ 6000 different enzymatic genes in a typical yeast
A bacterial genome
Metabolic engineering: genomes can be 
reprogrammed:
 Genomes can be reprogrammed, enzymes can be 
engineered
 Metabolic networks can be assembled on a 
genome wide scale
Synthetic biology: systematic modification 
of cells to achieve a new function
 Redesign of natural biological systems, 
 Industrial biotechnology applications: production of 
desired chemical compound by cells
Metabolic network in 
biological systems
Synthetic biology
13 Total R&D in Cleantech -- Lux Executive Summit, Boston, April 2012
































 Promising, fast-evolving technology (ongoing scientific progress)
 Versatile in terms of feedstocks
 Are able to target a variety of molecules with relatively low switching or 
arbitrage costs
 Industrial operations do not require a large facility/CAPEX/production 
volumes
The potential of aquatic phototrophs
Advantages:
o Cultivated on non-arable land and saline water (no 
competition with food crops) 
o No lignin production  (easier to valorize without harsh 
pretreatment) 
o Rich in lipids (High energy density feedstock for  
fuels/chemicals)
Solar energy = 4000 Kcal/m²/day
Dry biomass composition (Organic fraction)
Micro-Algae Grass
Saccharides 5 - 25% 35%
Lipids 20 - 40% 3%
Proteins 20 - 50% 25%
Fibres (lignin) - 37%
Algae:  Biomass production @ 2,5%  70 
T/ha/y (30% lipids), Lipid production @ 
2,5% and 30% lipids  23,000 l/ha/y
Terrestrial:  Biomass production 
Sorghum: 50 T/ha/y; Energy Cane: 75 
T/ha/y, Lipid production: Palm oil: 
6000 l/ha/y, Rapeseed: 1400 l/ha/y, 
Sunflower: 950 l/ha/y
Potentially significant advantages over terrestrial biomass, but substantial R&D 
efforts required to fulfill promise15 Total Confidential
BioTFuel






Black-liquor to DME 
demo
Network of Biotechnology Partnerships
Industrial synthetic
biology platform













Network of collaborations with academic labs and startups to develop key technology
bricks, and build biotech know-how
Identify and incubate future projects through active scouting and consortia
Pilot/demo projects on thermochemical transformations and on PLA
Investment in partners at periphery of strategic focus through corporate venture fund
Engineering metabolism through 
synthetic biology
Created in 2003  with technology developed by Prof. Jay 
Keasling (UC Berkeley)
Mission: produce terpenoids « on demand », based on its 
versatile synthetic biology platform and its mevalonate
pathway expertise
Proof of concept with artemisinin in 2005 (anti-malarial 
drug, now under development by Sanofi-Aventis)
Facilities
• 2 R&D and pilot sites (lab scale to 5 m3 - US, BR)
• Demo / toll productions (up to 2* 250 m3 - US, BR - EU)
• Industrial plant planned  in 2013 (>100 m3 - BR)
Key success factors
 Development of a unique industrial synthetic 
biology platform, and is recognized as « best-in-
class »
 Targeting value-added molecules (cosmetics, 
surfactants, isoprene), large market molecules
(jet-fuel, diesel) and developing access to 
markets through partnerships
 Securing access to feedstocks in Brazil through 
the appeal of its technology
Amyris in a nutshell
Employees
• >300 employees (US, Brazil)
+ Family of terpenoid
compounds
+ =




jet fuel              
malaria drug 





TOTAL property - CONFIDENTIAL18
Farnesene
Competitive advantages of Amyris & Total together: 
differentiating technology, integration and market access
Amyris: leader in 
Synthetic 
biology 
First generation in 
Feedstock sourcing








Total and Amyris partnership model: 
22% equity stake, broad-spectrum R&D collaboration, 








Brazil on sugar cane




record for strain 
improvement
Total: industrial scale-
up and chemistry 
know-how




Amyris core research capability is engineering microbes to make 















Jet / Gasoline PrecursorsIsoprene
IS




1. Engineering of terpenoids pathways in E.coli and Yeast
2. Industrial synthetic biology platform
 Strain development and optimization
 Fermentation scale-up
 Generic: currently applied to terpenoids pathway in yeast cells, but applicable to other pathways and other hosts
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Target molecules:
 Currently: artemisinin (anti-malarial drug), farnesene (C15), isoprene (C5),  C20-30 for lubricants, C10 for biojet
 Potential: 
 All terpenoids (combinations of C5 units) 














Automated Strain Engineering Technology
Strain design idea
Computerized desired construction sketch
 Overproduce intermediates compounds
 Deregulate pathway
 Shutdown carbon leak
 Introduce new pathway




Large set of rational designs can be 
tested
1,200 constructs can be 
generated in 1 cycle
Random mutagenesis to sample non-
obvious regions of sequence space
- CDGEN - 18/05/2011 - Biotechnologies (2nd session)22
actual
Stitches: Combined DNA piece
actual
Rabits can be combined together to make all the 
desired modification in 1 step only
x1,200
actual
All the stitches from a cycle are integrated into a 
parental strain to yield next gen strains
Four types of technologies and a strong team to help Amyris leverage
technology into an industrialization platform for biosourced molecules
Complementary technologies developed through collaborations with academic
labs and early-stage startups (JBEI, Toulouse, Wageningen, Cellectis, Boston 
Area Startup…)
Anchor and develop team, expertise and network through long-term partnerships
Amyris































































 • Mevalonate Pathway
• Industrial synthetic 
biology platform
• Fermentation scale-up 
platform


























 Develop bioenergy crops; 
Modify quantity and 
composition of sugars in cells 
from plant walls
Deconstruction
Separation and isolation of 
fermentable sugars and lignin
Fuels Synthesis
 New metabolic pathways, cell toxicity 
and stress, high concentrations
 Target products: alcohols, alkanes, 
esters, cyclic alkane and alkene
• JBEI is a six institution partnership led by Lawrence Berkeley National 
Laboratory and headed by Jay Keasling 
– J. Keasling has investigated the main pathways of interest to produce 
biofuel and biosourced chemicals (fatty acids, terpenes and polyketides) 
and co-founded LS9 and Amyris
– JBEI is one of the  3 Bioenergy Research Centers established by the DOE  




Polyketide synthases (PKSs) are natural modular enzymes that produce Polyketides, a large class of
secondary metabolites with considerable structural heterogeneity.
Naturals polyketides provide a broad range of clinically effective drugs

















Module 2 Module 3 Module 6
Module 4
Module 5Load
































13 Narbonolide PKS pathway 
Erythromycin Rifamycin Monensin Avermectin
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natural product and natural product-derived compounds approved as drugs in the 2005–2007 period
were polyketides.
Synthetic biology tools applied to polyketide synthase systems could enable the custom design of a
wide range of molecules with utility for several applications, including biofuels and chemical.
Production of 1-hexene using PKS systems
Understanding each piece of the PKSs “lego” and reassembling catalytic units into novel
combinations could potentially yield hundreds of millions of compounds compared with the 10,000
polyketides described from all natural sources.
PKS modules and chemical 
structures associated
To tap into the potential of synthetic PKS pathways, we need to better understand :
 The nature of the linker between 2 modules
 How these multi-enzymatic complexes fold
 The nature and availability of PKS cofactors
 The best hosts for their production
Joint project
3 designed pathways have been introduced in E. coli and several streptomyces strains
Interestingly, we were able to detect 1-hexene in some strains and only intermediates in
others.
Ongoing: in vitro experiments to understand pathway bottlenecks, search for the best
promoters to improve expression.
Efficient export of target compounds from microorganisms
Microorganisms manage the import of nutrients and export of a variety of compounds. Many of these








Diagrammatic comparison of the five families of efflux pumps.
Piddock L J V Clin. Microbiol. Rev. 2006; doi:10.1128/CMR.19.2.382-402.2006
Understanding these systems could be key to the industrial production of biomolecules.
Escherichia coli cell.
 Intracellular accumulation of target compounds pushes back on the biosynthetic pathway turnover, impairing
production levels.
 Several target compounds are highly toxic to cells: means to effectively export these compounds would significantly
help increase production yields.
 An efficient export system could decrease the cost of extracting products from cells.
Joint project on increasing resistance to 1-hexene through efflux pumps
1-hexene is a toxic molecule for many microbial strains.
We identified 2 distinct pumps capable of increasing tolerance to 1-hexene.
Current work: increase resistance phenotype through lab evolution, test resistance
phenotype in a variety of strains
Exploring the potential of aquatic 
phototrophs








We started learning and investigating with partners
 AlgaeParc (process platform)
 Greenstars (network of academic R&D platforms)












Cellectis’ genome engineering technology
 Meganucleases are sequence-specific, naturally occurring “DNA  scissors”, 
found in bacteria, yeast, algae and some plant organelles.
 600 such meganuclease are known: Cellectis engineers them to diversify their
targets to specific DNA sites
 Technology has been proven in a variety of systems.
31 Total Confidential
Total – Cellectis R&D partnership
Exploratory research into microalgae-based substitutes for oil products
- 1st phase (one year)
Goal: develop genome engineering methods and tools on specific 
phototrophic species selected for their phenotypes well suited to production 
and harvesting 
- Potential 2nd phase (two-three years)
Goal: engineer other phenotypic traits with a view to producing specific oil-
derived compounds
32
Cellectis' genome engineering technology will accelerate the domestication
and engineering of selected microalgal species, paving the way for the
production of oil products substitutes.
Conclusions
Biotechnology strategy: develop advanced biofuels














Secure viable feedstocks supply




Develop efficient production routes 
Integrate technology bricks into a viable industrial production 
route from sugars to advanced biofuels and commodity
chemicals
Keep exploring complementary or alternative routes
34
R&D to prepare future access to 
other feedstocks: forest
residues, waste, CO2
to diesel, jet fuel, lubes and 
chemicals using Amyris platform + 
complementary technologies
Building the supply base for large volumes of cheap biomass feedstock
 Global studies show potential …
 …but local potential, constraints, choices, and practices matter more
 Sugar in Brazil is currently scalable, sustainable, low-carbon…low cost ?
 When will cheap sugars from lignocellulosis be available at scale ?
Biomass transformation routes must meet environmental standards
 Feedstock largely drive GHG emissions performance
Current challenges in industrial biotechnology
Total R&D in Biotech, BIO Industrial Biotech Congress, Orlando, April 2012
 Land and water are scarce resources, for which arbitrage has to happen
 Mandates set the stage for (ground) transportation biofuels industry development ; no 
equivalent indicators / drivers for biobased chemicals or jet…yet?
 Stable and sound regulatory environment needed for the long road ahead
Production costs need to reach economically viable levels, so emerging industry
players developing advanced transformation technologies need to :
 Scale-up production routes to commercial-scale operations
 Secure access to feedstocks to demonstrate overall costs
 Develop technology from low-volume high-margin to high-volume low-margin products
35
Choice of best industrial host to produce a given molecule, with a given
pathway and C-source ? 
 Development of  genetic and modeling toolkit for « non-classical » hosts.
Systematic vs tailored approaches to metabolic engineering: which is
applicable when ? How to best combine them ?
Genetic (in)stability of engineered strains
Challenges in metabolic engineering for fuels and 
chemicals
Scale-up: codevelop and optimize strains and fermentation, purification, and 
downstream processing.
Expand the range of processable feedstocks: C5, CO2 & others
Tools for metabolic engineering and synthetic biology
 Automated strain construction, better HTS, modeling and CAD tools, management of 
genotype/omics/phenotype info…
And of course: new and creative metabolic designs !
36
Thank you and  have 
a great conference !
Total R&D in Biotech, BIO Industrial Biotech Congress, Orlando, April 201237
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 Implement new pathways 
assembled from other species
 Increase pools of all metabolic 
intermediates
 Deregulate entire pathway 



















In 2011, our R&D budget 
was $950 million.














IN CAPITAL EXPENDITURE IN 201192,855 EMPLOYEES
OPERATIONS IN SALES OF
SHARE OF GROSS 
CAPITAL EXPENDITURE 
DEVOTED TO UPSTREAM 
OPERATIONS
NET INCOME











Import huiles en EU27 pour  EMHV (kt)





 Strong sensitivity to regulatory changes,























• Massive export of surplus US production
• Brazil started importing ethanol because of lower ethanol production (agriculture +
arbitrage favor ing sugar), higher demand (flexfuel) and stronger real
• Growing share of oil transformation in producing countries (Asia, Argentina).
• New mandates create dnew fluxes (Péru B5),…
• Technology Summary: 
1. Engineering of terpenoids pathways in E.coli and Yeast
2. Industrial synthetic biology platform
• Strain development and optimization
• Fermentation scale-up
• Generic: currently applied to terpenoids pathway in yeast cells, but applicable to other pathways and other hosts
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Target molecules:
– Currently: artemisinin (anti-malarial drug), farnesene, isoprene,  C20-30 for lubricants, C10 for biojet
– Potential: 
• All terpenoids with mevalonate pathway: 50000 molecules, combinations of C5 units























HTS data are analyzed and compared to the theoretical expectations to improve the next 
iterations
4
Are biologists imitating chemists or vice-versa ?
“Synthesis and analysis 
are complementary. 
(a) In organic 
chemistry, analysis and 
synthesis were both 
critical in determining 
fundamental principles of 
chemical structure and 
reactivity. Synthetic 
molecules have been used 
for a wide variety of 
applications. 
(b) Similarly, synthetic 
approaches will 
complement analytical 
methods in elucidating 
biological principles, and 
synthetic cellular systems 
will prove highly useful. »44 Yeh & Lim, Nature Chemical Biology, 2007
Challenges in exploiting phototrophs  
R&D opportunities
Low maturity of technologies:
 Strain: No domesticated strain. 
Utilization of GMO strain maybe 
needed
 Bio-engineering: less knowledge than 
yeast
 CO2: Co-location with a plant could 
be needed
R&D opportunities:
 Identify natural strains with good 
“starting” traits
 Which family of phototrophs to choose: 
cyanobacteria – diatoms – micro-algae –
macro-algae ?
 Bioengineer traits desirable for 
efficient, high yield, robust 
 Process: no integrated process 
operated at scale
 Energy: need to prove energy positive 
process
⇒ High costs of production
production of lipids or other 
molecules: 
 Eg: lipid production over cell growth in 
single stage process, control of lipid 
composition, reduce nutrient 
consumption, produce other molecules 
through new pathways, secretion
 Demonstrate process robustness 












Traditional metabolic engineering strategies an only make one 
modification at a time:
 Focus carbon flux  OR
 Deregulate a section of the pathway  OR
 Increase the pool of a specific intermediate compound  OR
 Replace one enzyme by a more efficient variant from biodiversity or 
engineered














Traditional tools applied sequentially:
• tedious sequential process to explore large space of possible designs
• Modifications provoke side effects and readjustments, 
 Systematic increases in yield call for more global and systematic approaches
Carbon flux focus
Deregulation of 
pathway section
